Crossmark

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Crossref DOI link: https://doi.org/10.1186/s13058-020-01303-9

Published Online: 2020-06-23

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guo, Hua

Ding, Qingqing

Gong, Yun

Gilcrease, Michael Z.

Zhao, Min

Zhao, Jun

Sui, Dawen

Wu, Yun

Chen, Hui

Liu, Hui

Zhang, Jinxia

Resetkova, Erika

Moulder, Stacy L.

Wang, Wei-Lien

Huo, Lei https://orcid.org/0000-0001-7533-9082
License Information

Text and Data Mining valid from 2020-06-23

Version of Record valid from 2020-06-23
More Information

Article History

Received: 7 January 2020

Accepted: 1 June 2020

First Online: 23 June 2020

Ethics approval and consent to participate

: This study was approved by the institutional review board of The University of Texas MD Anderson Cancer Center. Individual consent was waived.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below